Jason Crites is the Founder/CEO of Assurance Health Data (AHD), a health technology company that has created the trusted third-party health data platform and marketplace. After his father's aggressive late-stage prostate cancer and his nephew's rare Leigh's Syndrome diagnosis, Jason became obsessed with solving the problems researchers face in obtaining and sharing data. After 18 years at IBM where he was one of the creators of the federated data model and the global storage solution – closing over $2 Billion in deals and optimizing the data infrastructure of many of the Fortune 500 – he founded AHD with the mission to make health data liquid.
AI and Data Sciences Showcase:
Assurance Health Data
Assurance Health Data is a trusted, third-party clinical data platform and market, enabling data sharing at scale across healthcare providers, researchers, patients, as well as diagnostic and life sciences companies to solve the biggest data problems in healthcare — together.
Enabling Trust for Rare Clinical Quality Data
Real-World Evidence requirements for precision medicine surpass existing data company’s approaches. We will discuss the AHD Data Network and how we enable creating and sharing of the world’s highest-quality, nuanced and difficult-to-obtain datasets and patient samples.
Keith Yamamoto, UCSF
Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support